6 edition of Antisense therapeutics found in the catalog.
Includes bibliographical references and index.
|Statement||edited by M. Ian Phillips ; foreword by Stanley T. Crooke.|
|Series||Methods in molecular medicine -- 106.|
|Contributions||Phillips, M. Ian.|
|LC Classifications||RM666.A564 A585 2005|
|The Physical Object|
|Pagination||xii, 327 p. :|
|Number of Pages||327|
|ISBN 10||1588292053, 1592598544|
|LC Control Number||2004006680|
MicroRNA-masking antisense oligonucleotide technology (miR-mask) is another strategy for miRNA-based therapeutics. In contrast to miRNA sponges, miR-masks consist of single-stranded 2’-O-methyl modified antisense oligonucleotides that are fully complementary to the expected miRNA binding site in the 3’-UTR of target mRNA [ 43 ].Cited by: 2. References. 1. Ackermann EJ, Guo S, Benson MD et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid 23(3), – (). Crossref, Medline, CAS, Google Scholar; 2. Chiriboga CA, Swoboda KJ, Darras BT et al. Results from a Phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal Author: Daniel A Norris, Noah Post, Rosie Z Yu, Sarah Greenlee, Yanfeng Wang.
Get this from a library! Antisense Therapeutics. Methods in Molecular Medicine.. [Sudhir Agrawal] -- Leading researchers offer an authoritative survey and analysis of the latest findings on the rapid development of antisense oligonucleotides therapeutic . Antisense Therapeutics. Antisense therapeutics are used to treat certain types of genetic disorders or infections. Antisense therapeutics can work by making a nucleic acid that can "turn off" the particular gene that is causing the disease.
Antisense oligodeoxynucleotides and antisense RNA allow pharmacologists to design agents that are more predictable and selective in their actions. This book is a practical, state-of-the-art treatise on antisense oligodeoxynucleotide and antisense RNA technology and the potential application of these strategies in therapeutics. Tegsedi (inotersen) (Ionis Pharmaceuticals/Akcea Therapeutics) is a chemically modified 20 mer antisense oligonucleotide (ASO), which is complementary to a conserved region of the 3’UTR of the TTR transcripts present in both the wild type and disease-causing : Sarah Bajan, Gyorgy Hutvagner.
Nuclear waste management
At home and abroad
Gandhi and the Indian national revolutionaries
Politics of scheduled castes in Bihar
Pesticide safety and the commercial ground sprayer.
Roller skating tests and competitions of the United States of America.
EEC legislation applicable to the cereal sector.
Advances in economic theory
History of the Apsley and Bathurst families.
Golf lessons from the pros.
Thoughts on evaluation in higher education
Medicare reimbursement to competitive medical plans
Midnight in the Garden of Good and Evil
Radnorshire in history, topography and romance.
In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers.
The author Antisense therapeutics book clearly an authority in the field and has extensive knowledge about the potential of antisense therapeutics. Features: Antisense approaches that are currently under investigation to treat various diseases are covered.
In particular, this book discusses the usefulness of antisense to treat cardiovascular disease, cancer, and various gastrointestinal Pages: Leading researchers offer an authoritative survey and analysis of the latest findings Antisense therapeutics book the rapid development of antisense oligonucleotides therapeutic and their application in various in vivo model systems.
The book's high-profile contributors provide timely accounts of their state-of-the-art strategies. Antisense Therapeutics. Editors: Phillips, M. Ian (Ed.) Free Preview. Buy this book eBook ,69 € price for Spain (gross) Buy eBook ISBN ; Digitally watermarked, DRM-free; Included format: EPUB, PDF; ebooks can be used on all reading devices; Immediate eBook download after purchase Brand: Humana Press.
Divided into five parts, the book begins with a thorough introduction to the mechanism of antisense drug action including the RNase H mechanism, small RNA silencing pathways, and the potential therapeutics of splice switching : $ Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide covering all key aspects of this increasingly popular area of pharmacology and biotech and pharma research, from the basic science behind antisense oligonucleotides chemistry, toxicology, manufacturing, to safety assessments, the design of therapeutic Format: Hardcover.
Antisense oligonucleotide-based therapeutics involves downregulation of gene expression. RNA-based drugs that include antisense oligonucleotides bear great therapeutic potential toward treatment of various diseases by altering RNA and/or reducing, restoring, and modifying protein expression through multiple molecular : Shashwat Sharad.
About this book. Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases, as well as other severe and rare diseases.
Antisense Therapeutics Limited () is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.
Use of antisense oligonucleotides is a growing field of pharmaceutical and biotech companies and research programs for treatment of several diseases. This book summarizes and presents the best updates, therapeutic principles, methods, and applications in the field and offers meaningful information to move treatment discovery forward.
Antisense Therapeutics Sudhir Agrawal Leading researchers offer an authoritative survey and analysis of the latest findings on the rapid development of antisense oligonucleotides therapeutic and their application in various in vivo model systems. Applied Antisense Oligonucleotide Technology provides the basic concepts as well as the practical concerns associated with the use of antisense oligonucleotides to modify gene expression.
Chapters include oligonucleotide chemistry, DNA triplex formation, delivery mechanisms, pharmocokinetics, toxicity, : C.
Stein. Product Information. This book covers the therapeutic applications of antisense therapeutics. Organized into disease states, it includes the most forefront approaches to the development and current research in antisense-based therapies of human diseases including AIDS, cancer, cardiovascular disease and hepatitis.
Delivery Strategies for Antisense Oligonucleotide Therapeutics (CRC Press Revivals) 1st Edition. by Saghir Akhtar (Editor) ISBN ISBN Why is ISBN important.
ISBN. This bar-code number lets you verify that you're getting exactly the right version or edition of a book. Author: Saghir Akhtar. Antisense therapeutics Agrawal and Zhao Conclusions Antisense was thought to be a simple and rational therapeutic approach based on specific inhibition of gene expression.
Evidence in the literature indicates that the situation is. Antisense rel A in Cancer. Continuous Infusion of Antisense Phosphorothioate Therapeutics. Protein Kinase-A Directed Antisense Therapy of Tumor Growth In Vivo: The Antisense Effects Outlast Antisense Survival.
Antisense Therapeutics in the Central Nervous System: The Induction of c-fos. Comparative Pharmacokinetics of Antisense Oligonucleotides. Antisense therapeutics. [M Ian Phillips;] -- The complete sequencing of the human genome in April demonstrated the presence of thousands of targets for antisense oligonucleotides.
Phillips (University of South Florida) assembles a team of. Extensively revised and updated, Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition reflects the logarithmic progress made in the past four years of oligonucleotide-based therapies, and, in particular, antisense therapeutics and research.
Interpreting lessons learned from the clinical trials of first generation drugs, the book. Antisense oligonucleotides (ASOs) have been validated as therapeutic agents and an important tool in molecular biology.
Indeed, ASOs are used either in vitro or in vivo to generate mRNA selective knockouts. They can be used for human therapy since ASOs can inhibit specifically target genes especially whose are difficult to target with small molecules inhibitors or Author: Sara Karaki, Clément Paris, Palma Rocchi.
Get this from a library. Antisense therapeutics. [M Ian Phillips;] -- Announcement of the complete sequencing of the human genome in April demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of.
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to cause a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA.Book Description.
Extensively revised and updated, Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition reflects the logarithmic progress made in the past four years of oligonucleotide-based therapies, and, in particular, antisense therapeutics and research.
Interpreting lessons learned from the clinical trials of first generation drugs, the book .The field of antisense therapeutics has attracted great interest during the past decade. A large body of literature has recently appeared in which the antisense mechanism is claimed to be involved and a number of human clinical trials are underway.